Introduction {#s1}
============

The MIT/TFE family of bHLH leucine zipper transcription factors includes the *MITF, TFEB, TFE3* and *TFEC* genes, which are master regulators of cell homeostasis, growth and differentiation ([@bib35]; [@bib57]; [@bib58]). All family members are able to both homodimerize and heterodimerize with each other through their bHLH-LZ domain ([@bib21]). These transcription factors bind a DNA sequence called the M-box and a non-canonical E-box sequence (TCATGTG, CATGTGA or TCATGTGA) ([@bib21]; [@bib1]). A large body of evidence indicate that they play an important role in many cellular and developmental processes.

*TFEB* was found to regulate a large gene network, named *Coordinated Lysosomal Expression and Regulation (CLEAR*). This network includes many genes involved in lysosomal biogenesis and autophagy ([@bib57]; [@bib45]). Several studies have shown that TFEB responds to a variety of stimuli and stress conditions, such as starvation, and acts as a master regulator of the lysosomal-autophagic pathway and of cellular clearance ([@bib10]; [@bib54]; [@bib57]; [@bib58], [@bib60]; [@bib59]; [@bib42]). Recent data indicate that the *TFEB* and *TFE3* genes regulate a similar set of genes and have partially redundant function ([@bib41]).

Renal cell carcinomas originate from the renal epithelium and include several subgroups defined according to their histological phenotype. The most frequent RCCs are papillary (15--20%), Clear Cells (65--70%) and cromophobe (5--10%) ([@bib2]). In these categories, mutations in 12 different genes (*VHL, MET, FH, FLCN, SDHB, SDHC, SDHD, TSC1, TSC2, PTEN, MITF* and *BAP1*) have been associated with an increased susceptibility of developing RCC ([@bib36]). *TFE*-RCCs are a group of renal cell carcinomas caused by chromosomal translocations involving *TFEB* and *TFE3* genes ([@bib23]) and representing around 2% of all RCCs ([@bib27]), and almost 12% of papillary type II RCCs ([@bib37]).

Recent TCGA analyses revealed that the gene fusions caused by chromosomal translocations involving *TFEB* and *TFE3* are the only recurrent translocations in the kidney ([@bib37]; [@bib40]). In the case of TFEB, a recurrent chromosomal translocation *t*(*6;11*) (*p21;q13*) involves the promoter of the non-coding Alpha gene and the transcription factor EB (*TFEB*) ([@bib3], [@bib6]). As a consequence, *TFEB* falls under the control of the strong Alpha gene promoter, resulting in a high (up to 60-fold) overexpression of a structurally normal TFEB protein ([@bib30]). More recently, additional TFEB translocation partners were described, such as the *KHDBRS2* (*inv*(*6*) (*p21;q11*)) ([@bib40]) and the *CLTC* (*t*(*6;17*) (*p21;q23*)) ([@bib17]) genes. Tipically, these tumors show nests of epithelioid cells with clear cytoplasm, known as clear cells (CCs), and clusters of small cells, usually around the multi-layered basement membrane (mBM) made up of hyaline material ([@bib6]). Some cases presented with areas of a tubular or cystic structure covered by a single layer of flattened cuboidal to columnar cells with clear cytoplasm, mimicking clear cell RCC with cystic changes ([@bib51]). Currently, *TFEB* translocation, overexpression and nuclear localization are considered as a diagnostic marker for the disease. Initially, these tumors were mainly observed in pediatric patients, but now they are considered relatively common in young adults ([@bib27]). The mechanisms leading from *TFE3/TFEB* gene overexpression to kidney tumor development remain largely uncharacterized, thus the need for modeling these diseases in experimental animal systems for the identification of effective targeted therapies.

Here, we show the generation and characterization of two different transgenic mouse lines that overexpress TFEB specifically in the kidney in a constitutive and inducible manner, respectively, which recapitulate both the cystic changes and the cancer phenotype of the human pathology. An extensive molecular and biochemical characterization of kidneys, as well as of primary kidney cells, derived from these mice revealed a significant hyper-activation of the WNT pathway, suggesting that this signalling pathway plays an important role in TFEB-driven kidney cancer. Finally, the use of small molecules able to specifically inhibit the WNT pathway resulted in a significant rescue of both the cystic and cancer phenotypes. These data may open the way to a new therapeutic strategy for this type of tumors.

Results {#s2}
=======

Generation of the transgenic mouse lines {#s2-1}
----------------------------------------

To study the mechanisms underlying tumor development in *TFEB*-fusion *RCC,* we generated a transgenic mice that specifically overexpress *TFEB* in the kidney. We crossed a previously generated *Tfeb* conditional overexpressing mouse line that carries *Tfeb-3xFlag^fs/fs^* under the control of a strong chicken beta-actin (CAG) promoter ([@bib58]), herein referred to as *Tfeb^fs/fs^,* with the *Cdh16^Cre^ (Cadherin16^Cre^*) mouse line, in which the *Cre* recombinase is specifically expressed in renal tubular epithelial cells starting from embryonic stage E12.5 ([@bib61]).

In addition, to assess the effects of *Tfeb* overexpression during kidney development, we generated a second transgenic line by crossing the *Tfeb^fs/fs^ *mice with a mouse line that carries a tamoxifen-inducible *CreErt2* element under the control of a *Cdh16* promoter (*Cdh16^CreErt2^*promoter) ([@bib31]) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). *Cdh16^Cre^::Tfeb^fs^* and *Cdh16^CreErt2^::Tfeb^fs^ *double heterozygous mice were generated from these crossings ([Figure 1---figure supplement 1B and C](#fig1s1){ref-type="fig"}). We checked both the constitutive and inducible lines for renal *Tfeb* overexpression and confirmed that *Tfeb* mRNA levels were highly increased, and further increasing with time ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Consistently, immunoblot experiments revealed increased levels of Tfeb-3xFLAG protein in kidneys from *Cdh16^Cre^::Tfeb^fs^* and *Cdh16^CreErt2^::Tfeb^fs^ *mice ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}).

Progressive cystic pathology in transgenic mouse lines {#s2-2}
------------------------------------------------------

At sacrifice, kidneys from adult *Cdh16^Cre^::Tfeb^fs^* and tamoxifen-treated *Cdh16^CreErt2^::Tfeb^fs^* mice completely filled the abdominal cavity ([Figure 1A](#fig1){ref-type="fig"}). An increase in kidney size from *Cdh16^Cre^::Tfeb^fs^* mice was observed starting at P12, with a sensible increase in size detected at P30 ([Figure 1B](#fig1){ref-type="fig"}). A striking increase in the Kidney to Body Weight (KW/BW) ratio was also observed at this stage ([Figure 1C](#fig1){ref-type="fig"}). A severe enlargement of the kidneys and a significant increase in the Kidney to Body Weight (KW/BW) ratio were also observed in *Cdh16^CreErt2^::Tfeb^fs^* mice induced with tamoxifen at several developmental stages (P12, P14, P30) ([Figure 1---figure supplement 2A and B](#fig1s2){ref-type="fig"}). These abnormalities were less severe in mice induced at P30 ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). Survival time of *Cdh16^Cre^::Tfeb^fs^ *mice was approximately 3 months ([Figure 1D](#fig1){ref-type="fig"}). Interestingly, a late induction of *Tfeb* overexpression in *Cdh16^CreErt2^::Tfeb^fs^ *mice resulted in a slower development of the phenotype, with less severe kidney enlargement and overall increase in the survival rate ([Figure 1D](#fig1){ref-type="fig"}). Renal function from *Cdh16^Cre^::Tfeb^fs^ *and *Cdh16^CreErt2^::Tfeb^fs^ *mice was severely affected, as observed by the strong increase in blood urea and albuminuria ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). High-frequency ultrasound and histological analysis of kidneys from both *Cdh16^Cre^::Tfeb^fs^ *and *Cdh16^CreErt2^::Tfeb^fs^ *mice revealed the presence of a severe cystic disease ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2D and E](#fig1s2){ref-type="fig"}). In *Cdh16^Cre^::Tfeb^fs^ *mice, small cysts arose mainly from the cortex and outer medulla at P12 and became significantly enlarged at P30. At P90, kidney architecture was completely disrupted by cysts ([Figure 1F](#fig1){ref-type="fig"}). *Cdh16^CreErt2^::Tfeb^fs^ *mice induced at P12 with tamoxifen and sacrificed at P90 showed a higher number of smaller cysts in both cortex and outer medulla ([Figure 1F](#fig1){ref-type="fig"}). Cysts were also observed in *Cdh16^CreErt2^::Tfeb^fs^ *induced at P14 and, to a lesser extent, at P30 ([Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}). Tubular epithelial cells lining the cysts showed high levels of cadherin 16, indicating the presence of *Cdh16^Cre^*-mediated *Tfeb* overexpression in these cells ([Figure 1G](#fig1){ref-type="fig"}). Histological analysis revealed that cysts from *Cdh16^Cre^::Tfeb^fs^ *mice were positive for AQP2 and THP and negative for megalin, indicating that they originate from collecting ducts and distal tubules and not from proximal tubules. Notably, the largest cysts were almost completely negative to all tubular markers, suggesting that they became undifferentiated. Conversely, cysts from *Cdh16^CreErt2^::Tfeb^fs^ *mice were positive to megalin and THP, indicating that they arose from proximal and distal tubules ([Figure 1H](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). These differences in cyst origin have already been described in other polycystic kidney disease mouse models and have been attributed to intrinsic differences of specific renal segments at different developmental stages ([@bib32]; [@bib20]; [@bib34]; [@bib49]).10.7554/eLife.17047.002Figure 1.*Tfeb* overexpressing mice display cystic kidneys.Morphological analyses were performed on *Cdh16^Cre^ *and *Cdh16^Cre^::Tfeb^fs^,* and on tam-treated *Cdh16^CreErt2^* and *Cdh16^CreErt2^::Tfeb^fs^* mice. (**A**) Representative images of the abdominal cavity at P90. (**B**) Kidney size at different stages (p=days post-natal). (**C**) Relative ratio of kidney-to-body weight (KW/BW). Data from males (M) and females (F) are shown separately as means of *Cdh16^Cre^::Tfeb^fs^* to *Cdh16^Cre^* KW/BW ratio. Three-way Anova was applied (factors: gender, time, genotype). (**D**) Evaluation of the survival of *Cdh16^Cre^::Tfeb^fs^* and tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice. Mantel-Cox test was applied (*Cdh16^CreErt2^::Tfeb^fs^* tam P12/tam P14 p-value 0.02; *Cdh16^CreErt2^::Tfeb^fs^* tam P12/P30 p-value\<0.0001). (**E**) Haematoxylin and Eosin (HE) staining of kidneys. Enlarged panels show cyst growth over time. (**F**) Number (left graph) and area (right graph) of kidney cysts in *Cdh16^Cre^::Tfeb^fs^,* and *Cdh16^CreErt2^::Tfeb^fs^* mice. Number of cysts is shown as an average (± SEM) with bars sub-divided according to the dimension of the cysts. Cyst areas are presented as independent values (dots) with lines representing the means. Three-way (cyst number) and two-way (cyst area) Anova was applied. Cor, cortex; oMed, outer medulla; iMed, inner medulla. (**G**) Cadherin16 (CDH16) staining of kidneys from P30 mice. (**H**) Megalin, THP and AQP2 stainings in P90 *Cdh16^CreErt2^::Tfeb^fs^* mice. (**I**) PAS and Sirius Red staining. PAS staining shows the presence of single-layered or multi-layered cysts, and the presence of Clear Cells (CCs). SR staining shows areas of interstitial fibrosis, multi-layered basement membrane and protein casts. Asterisks, protein casts; sCy, simple Cysts; mCy, multilayered Cy; IF, Interstitial Fibrosis; mBM, multi-layered Basement Membrane. (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.002](10.7554/eLife.17047.002)10.7554/eLife.17047.003Figure 1---figure supplement 1.Generation of transgenic mouse lines with kidney-specific *Tfeb* overexpression.(**A**) Map of the transgene: *Tfeb*-3xFLAG was inserted after the chicken actin promoter (CAG) and the chloramphenicol acetyltransferase (CAT)-SV40pA flanked by loxP sites. The latter can be removed by CRE recombinase, resulting in the overexpression of the *Tfeb* gene under the control of the strong CAG promoter. Two different CRE lines were used: (1) a constitutive kidney-specific *Cdh16^Cre^*(Cadherin 16) and (2) a tamoxifen-inducible *Cdh16^CreErt2^*. (**B**, **C**) Representative genotypes of littermates. (**B**) Lanes 1 and 4 indicate double heterozygous *Cdh16^Cre^::Tfeb^fs^* mice as they carry both the *Cdh16^Cre^* (420 bp *CRE* band, 200 bp *wt* band) and the *Tfeb^fs^* transgenes (700 bp) (M, marker; B, Blank). (**C**) Lane 1 indicates a double heterozygous *Cdh16^CreErt2^::Tfeb^fs^* mouse as it carries both the *Cdh16^CreErt2^* (507 bp *Cre* band, 388 bp *wt* band) and the *Tfeb^fs^* transgenes (700 bp). (**D**) Real-time PCR analysis of *Tfeb*-3xFLAG mRNA levels performed on *Cdh16^Cre^* and *Cdh16^Cre^::Tfeb^fs^* mice at different stages (P0, P12, P30) and on *Cdh16^CreErt2^*and *Cdh16^CreErt2^::Tfeb^fs^* mice induced with tamoxifen at P12 and sacrificed at P90. Values are shown as the average (± SEM) of at least three animals per time point and genotype (\*p\<0. 05, \*\*p\<0.01, two-sided, Student's *t* test). (**E**) Immunoblot analysis using an anti-Flag antibody to determine the expression of Tfeb-3xFLAG protein in *Cdh16^Cre^::Tfeb^fs^* and tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice. Each replicate is a different biological sample.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.003](10.7554/eLife.17047.003)10.7554/eLife.17047.004Figure 1---figure supplement 2.Renal-specific *Tfeb* overexpression results in kidney enlargement and failure.(**A**) Tamoxifen injection of *Cdh16^CreErt2^::Tfeb^fs^* mice at P12, P14 and P30 with representative images at the time of sacrifice (tam, tamoxifen). (**B**) Relative ratio of kidney to body weight (KW/BW) evaluated in tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice at P90. Two-way Anova was applied (factors: treatment, genotype). (**C**) Blood urea and albuminuria levels in *Cdh16^Cre^::Tfeb^fs^* and *Cdh16^CreErt2^::Tfeb^fs^* mice. Values are shown as means (± SEM) of at least three *Cdh16^Cre^::Tfeb^fs^* and *Cdh16^CreErt2^::Tfeb^fs^* mice and are normalized versus the control animals (*Cdh16^Cre^*and *Cdh16^CreErt2^*). (**D**) High-frequency ultrasound (HFUS) images of kidneys from P30 *Cdh16^Cre^::Tfeb^fs^* mice. (**E**) Images and PAS staining from tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice at P90.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.004](10.7554/eLife.17047.004)10.7554/eLife.17047.005Figure 1---figure supplement 3.Characterization of cyst origin in *Cdh16^Cre^::Tfeb^fs^* and *Cdh16^CreErt2^::Tfeb^fs^* mice.IHC staining of megalin, THP and AQP2 at different time points. Insets are enlargements of representative areas of interest. Larger cysts (denoted by an asterisk) are negative for all the markers tested. DTcy = Distal Tubules cysts; CDcy = Collecting Ducts cysts.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.005](10.7554/eLife.17047.005)

Cysts were lined by either a single layer-flattened cuboidal epithelium (sCy), or by a multilayer epithelium (mCy), indicating a de-regulation of tubular cell proliferation ([Figure 1I](#fig1){ref-type="fig"}). We also noticed the presence of very enlarged cells with a clear cytoplasm, which are commonly known as Clear Cells (CCs) ([@bib29]) ([Figure 1I](#fig1){ref-type="fig"}). Sirius Red staining showed the presence of fibrosis and protein casts and revealed a significant accumulation of collagen inside the affected kidneys, as well as the presence of regions surrounded by multi-layered basement membranes (mBM) ([Figure 1I](#fig1){ref-type="fig"}). Importantly, the presence of Clear Cells, fibrosis and mBMs are characteristic features of kidneys from human patients with *TFEB*-fusion *RCC* ([@bib51]).

Identification of papillary renal cell carcinoma and of liver metastases {#s2-3}
------------------------------------------------------------------------

^18^F-FDG PET analysis showed a higher glucose consumption in the kidneys of transgenic animals compared to controls, indicating a higher rate of glucose metabolism and suggesting a neoplastic transformation ([Figure 2A](#fig2){ref-type="fig"}). Similarly with PET analysis, HE and Ki67 stainings of the kidneys of *Cdh16^Cre^::Tfeb^fs^ *mice revealed progressive hyperproliferation, which evolved into Ki67-positive neoplastic papillae at 5 months ([Figure 2B](#fig2){ref-type="fig"}). Neoplastic nodules, micropapillae and Hobnail-like cells, and mitotic spindles were detected at P12, 1 month, and 5 months, respectively ([Figure 2C--F](#fig2){ref-type="fig"}). Focal microcalcifications ([Figure 2G](#fig2){ref-type="fig"}), together with Clear Cells, and nests of neoplastic cells ([Figure 2H](#fig2){ref-type="fig"}) were also detected in *Cdh16^CreErt2^::Tfeb^fs^ *mice.10.7554/eLife.17047.006Figure 2.Kidney-specific Tfeb overexpression is associated with cancer development in *Cdh16^Cre^::Tfeb^fs^* and *Cdh16^CreErt2^::Tfeb^fs^* mice.(**A**) ^18^F-FDG PET/CT scan on P30 *Cdh16^Cre^::Tfeb^fs^* mice. (**B**) HE and Ki67 staining performed on *Cdh16^Cre^::Tfeb^fs^* mice at P1, P12, P30 and 5 months. Beginning at P12 the increase in cyst size is associated with an increase in papillary proliferation that becomes completely neoplastic by 5 months. NP, Neoplastic Papillae. (**C**--**H**) Representative images of neoplastic lesions at different stages: (**C**) neoplastic nodules (arrows) in P12 *Cdh16^Cre^::Tfeb^fs^* mice; (**D**) micropapillae (arrows) and (**E**) hobnail-like cells (arrows) in P30 *Cdh16^Cre^::Tfeb^fs^* mice; (**F**) mitotic spindles (arrows) in 5-month-old *Cdh16^Cre^::Tfeb^fs^* mice; (**G**) microcalcifications (asterisk) in tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice induced at P14 and sacrificed at 5 months; (**H**) neoplastic nests (NN) and clear cells (CCs) in tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice induced at P12 and sacrificed at P90. (**I**) HE staining of neoplastic lesions invading the surrounding stroma (arrows) in *Cdh16^Cre^::Tfeb^fs^* and in tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice. (**L**) Liver metastases in 5 month-old *Cdh16^Cre^::Tfeb^fs^* mice stained for HE, Ki67, PAX8 and CK7.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.006](10.7554/eLife.17047.006)

Kidneys from both *Cdh16^Cre^::Tfeb^fs^*and *Cdh16^CreErt2^::Tfeb^fs^* mice presented numerous neoplastic lesions with both solid and cystic aspects, ranging from 0.102 to 2.93 mm and sometimes showing local invasion of the surrounding stroma ([Figure 2I](#fig2){ref-type="fig"}). Most importantly, liver metastases ranging from 0.9 to 3.8 mm, were found in both *Cdh16^Cre^::Tfeb^fs^*and *Cdh16^CreErt2^::Tfeb^fs^*mice. In *Cdh16^Cre^::Tfeb^fs^* animals, they were detected starting from P90 with an incidence of 23% (5 cases out of 21 *Cdh16^Cre^::Tfeb^fs^*mice older than 3 months). These metastases were positive for PAX8, that is a well-established marker for primary and metastatic RCC ([@bib44]; [@bib62]) and CDH16, which is a specific renal protein ([@bib62]), while they were negative for the bile ducts and cholangiocarcinoma marker CK7 (Cytokeratin 7), consistent with their renal origin ([Figure 2L](#fig2){ref-type="fig"}).

TFEB overexpression results in the induction of the canonical WNT pathway {#s2-4}
-------------------------------------------------------------------------

To characterize the molecular mechanisms and identify the relevant pathways leading from *TFEB* overexpression to tumor development, we performed transcriptome analysis on kidney samples from *Cdh16^Cre^::Tfeb^fs^ *and *Cdh16^Cre^*mice at P0 (GSE62977-KSP_P0 dataset) and at P14 (GSE63376-KSP_P14 dataset) (see Materials and methods) and found that *Tfeb* overexpression perturbed the kidney transcriptome in a statistically significant manner ([Figure 3---source data 1](#SD1-data){ref-type="supplementary-material"} and [2](#SD2-data){ref-type="supplementary-material"}, see also Materials and methods). Targeted analysis of the transcriptomic data revealed a significant induction of genes belonging to both ErbB and WNT signaling pathways. This was confirmed by real-time PCR performed on *Cdh16^Cre^::Tfeb^fs^ *mice at several developmental stages. Moreover, real-time PCR revealed an induction of *Myc* and *Axin2* genes, which are, together with *Ccnd1*, well-established WNT direct gene targets ([@bib14]) ([Figure 3A and B](#fig3){ref-type="fig"}, [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Kidneys from *Cdh16^CreErt2^::Tfeb^fs^* mice also had higher levels of all WNT-related genes that were identified in the constitutive line, and of many of the ErbB-related genes ([Figure 3---figure supplement 1A and B](#fig3s1){ref-type="fig"}).10.7554/eLife.17047.007Figure 3.Activation of ErbB and WNT signaling pathways in kidneys from *Cdh16^Cre^::Tfeb^fs^* mice.Transcriptional and biochemical analyses were performed on *Cdh16^Cre^* and *Cdh16^Cre^::Tfeb^fs^* mice. (**A**,**B**) Tables show the relative increase of genes related to the ErbB (**A**) and WNT (**B**) pathways in the microarray analyses performed on kidneys from P0 *Cdh16^Cre^::Tfeb^fs^* mice. Graphs show real-time PCR validations performed on kidneys from *Cdh16^Cre^::Tfeb^fs^* mice at different stages (P0, P12, P30). Data are shown as the average (± SEM) of at least three *Cdh16^Cre^::Tfeb^fs^* mice normalized versus wild-type mice. (**C**,**D**) Immunoblot analyses performed on (**C**) P30 kidney tissues and (**D**) primary kidney cells isolated from *Cdh16^Cre^::Tfeb^fs^* mice to evaluate ErbB and WNT activation status. Each replicate is a distinct biological sample. ErbB signaling was assessed by looking at phosphoAKT (Ser473) to total AKT ratio, and phosphoERK1 (T202/Y204)/ERK2(T185/Y187) to total ERK ratio; WNT signaling was assessed by quantifying β-catenin and CCND1 (Cyclin D1) protein levels. Graphs represent the densitometry quantification of Western blot bands. Values are normalized to actin when not specified and are shown as an average (± SEM) (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-sided, Student's *t* test).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.007](10.7554/eLife.17047.007)10.7554/eLife.17047.008Figure 3---source data 1.Complete list of 294 genes (represented by 361 probesets) significantly induced (FDR≤0.05) in the KSP_P0 microarray dataset (GSE62977).The genes are ranked by decreasing signed ratio (KSP_P0/CTL).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.008](10.7554/eLife.17047.008)10.7554/eLife.17047.009Figure 3---source data 2.Complete list of 628 genes (represented by 729 probesets) significantly induced (FDR≤0.05) in the KSP_P14 microarray dataset (GSE63376).The genes are ranked by decreasing signed ratio (KSP_P14/CTL).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.009](10.7554/eLife.17047.009)10.7554/eLife.17047.010Figure 3---figure supplement 1.ErbB and WNT transcriptional profiles in *Cdh16^CreErt2^::Tfeb^fs^* mice.Transcriptional analyses performed on *Cdh16^CreErt2^::Tfeb^fs^* mice. (**A**,**B**) mRNA levels of previously validated genes belonging to the WNT (left graphs) and ErbB (right graphs) signaling pathways assessed in P90 *Cdh16^CreErt2^::Tfeb^fs^* mice induced at (**A**) P14 and at (**B**) P30 with tamoxifen respectively. Data are shown as the average (± SEM) of at least *Cdh16^CreErt2^::Tfeb^fs^* mice and values are normalized to the wild-type line. (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-sided Student's *t* test).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.010](10.7554/eLife.17047.010)10.7554/eLife.17047.011Figure 3---figure supplement 2.Biochemical analysis of ErbB signaling.Immunoblot analysis performed on P90 kidneys from *Cdh16^Cre^::Tfeb^fs^* mice (**A**) and P90 *Cdh16^CreErt2^::Tfeb^fs^* animals induced with tamoxifen at P14 (**B**) and at P30 (**C**), respectively. Each replicate is a different biological sample. ErbB was analyzed by quantifying phosphoAKT (Ser473) to total AKT, and phosphoERK1 (T202/Y204)/ERK2(T185/Y187) to total ERK; graphs are the densitometry quantifications of Western blot bands normalized to wild-type line and are shown as an average (± SEM) (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-sided Student's *t* test).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.011](10.7554/eLife.17047.011)10.7554/eLife.17047.012Table 1.ErbB-related genes up-regulated in the microarray analyses. (**A**) List of six genes with a known role in ErbB signaling pathway which are significantly up-regulated (FDR≤0.05) following TFEB overexpression in KSP_P0 microarray dataset (GSE62977). (**B**) One gene with a known role in ErbB signaling pathway which are significantly up-regulated (FDR≤0.05) following TFEB overexpression in KSP_P14 microarray dataset (GSE62977).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.012](10.7554/eLife.17047.012)AProbe set IDGene symbolGene titlesigned_ratio (KSP_P0/CTL)1418350_at**Hbegf**heparin-binding EGF-like growth factor2,1948084731421943_at**Tgfa**transforming growth factor alpha1,92868881421134_at**Areg**amphiregulin1,6310118771424638_at**Cdkn1a**cyclin-dependent kinase inhibitor 1A (P21)1,6283618671425855_a\_at**Crk**v-crk sarcoma virus CT10 oncogene homolog (avian)1,5794331491450070_s\_at**Pak1**p21 protein (Cdc42/Rac)-activated kinase 11,507716537BProbe set IDGene symbolGene titlesigned_ratio (KSP_P14/CTL)1421134_at**Areg**amphiregulin1,22160579510.7554/eLife.17047.013Table 2.WNT-related genes up-regulated in the microarray analyses. (**A**) List of four genes with a known role in WNT signaling pathway which are significantly up-regulated (FDR≤0.05) following TFEB overexpression in KSP_P0 microarray dataset (GSE62977). (**B**) List of 10 genes with a known role in WNT signaling pathway which are significantly up-regulated (FDR≤0.05) following TFEB overexpression in KSP_P14 microarray dataset (GSE63376).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.013](10.7554/eLife.17047.013)A**Gene symbolsigned ratio (KSP_P0/CTL)Rnf146**1,700903945**Fzd3**1,650328884**Kdm6a**1,565386988**Ccnd1**1,377411994** BGene symbolsigned ratio (KSP_P14/CTL)Rhou**1,639718601**Plcg2**1,601227563**Gata3**1,358534898**Fbxw2**1,262750602**Mark2**1,248332335**Axin1**1,21985179**Tab1**1,217280695**Psmb3**1,211737817**Ndrg2**1,193338279**Chd8**1,185904267

Based on these results, we checked the activation of both ErbB and WNT signaling pathways. No evidence for an increase in the phosphorylation of AKT and ERK1/2 kinases ([@bib7]) was detected in P30 *Cdh16^Cre^::Tfeb^fs^* kidneys or in primary kidney cells obtained from transgenic mice ([Figure 3C and D](#fig3){ref-type="fig"}), indicating that the ErbB pathway was not induced. Erk1/2 activation, as detected by pERK1/2, was observed only at late stages ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). The same result was observed in P14 and P30 tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice ([Figure 3---figure supplement 2B and C](#fig3s2){ref-type="fig"}). Conversely, we detected increased levels of total β-catenin and CCND1 in P30 renal tissues and primary kidney cells ([Figure 3C and D](#fig3){ref-type="fig"}) and increased levels of active β-catenin and of pLRP6 (Ser1490)/ LRP6 ratio in P30 and P90 renal tissues from *Cdh16^Cre^::Tfeb^fs^*mice ([Figure 4A and B](#fig4){ref-type="fig"}) and in P14 and P30 tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Moreover, β-catenin and active β-catenin staining of renal sections from *Cdh16^Cre^::Tfeb^fs^* mice was significantly enhanced ([Figure 4C](#fig4){ref-type="fig"}). These results indicate the presence of a strong activation of the WNT signaling pathway in TFEB-overexpressing mice. Interestingly, the WNT pathway is known to play a role in renal cyst development ([@bib64]; [@bib55]) and renal tumor formation, such as in VHL syndrome ([@bib48]) and Wilm's tumor ([@bib26]; [@bib73]; [@bib24]). To investigate the role of TFEB in WNT pathway activation, we performed luciferase assays using a TOP-FLASH Luciferase WNT-reporter on immortalized kidney cell lines (HEK293 and HK2) co-transfected with *TFEB* and with both *β-catenin* and *TCF4* plasmids to stimulate WNT signaling. Luciferase activation was significantly higher in cells transfected with *TFEB* compared to controls without *TFEB*. No changes were observed when *TFEB* was transfected alone or only with *β-catenin* ([Figure 5A and B](#fig5){ref-type="fig"}). Together these data suggest that TFEB is able to enhance WNT pathway activation.10.7554/eLife.17047.014Figure 4.Molecular and histological analysis of WNT signaling.(**A**,**B**) Western blot analysis performed on (**A**) P30 and (**B**) P90 kidneys from *Cdh16^Cre^::Tfeb^fs^* mice to assess WNT signaling activation by looking at different proteins related to this pathway. Each replicate is a distinct biological sample. p-LRP6 (Ser1490)/LRP6, active β-catenin, β-catenin and p-GSK3β (Ser9)/GSK3β protein levels were quantified by densitometry analysis of the Western blot bands. Values are normalized to actin when not specified, and are shown as an average (± SEM) (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-sided Student's *t* test). (**C**) Immunohistochemistry staining of CDH16, β-catenin and active β-catenin proteins performed on P30 kidney tissues from *Cdh16^Cre^::Tfeb^fs^* mice.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.014](10.7554/eLife.17047.014)10.7554/eLife.17047.015Figure 4---figure supplement 1.Molecular analysis of WNT signaling pathway in *Cdh16^CreErt2^::Tfeb^fs^* animals.(**A**,**B**) Immunoblot analysis of WNT-related proteins performed on P90 *Cdh16^CreErt2^::Tfeb^fs^* animals induced with tamoxifen at P14 (**A**) and at P30 (**B**). Each replicate is a different biological sample. Graphs show densitometry analysis of the Western blot bands. Values are normalized to actin when not specified, and are shown as an average (± SEM) (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-sided Student's *t* test).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.015](10.7554/eLife.17047.015)10.7554/eLife.17047.016Figure 5.Inhibition of WNT signaling rescues the hyper-proliferative phenotype of kidney cells from *Cdh16/Tfeb* mice.(**A**,**B**) Activity of the TCF/LEF reporter *TOP-FLASH*. Luciferase activity after co-transfection of *β-catenin* and *TCF* plasmids in HEK293 (**A**) and HK2 (**B**) cells with and without *Tfeb* overexpression. Values are shown as an average (± SEM) of each point in duplicate, normalized to the Renilla values and to the basal condition. Data are representative of three independent experiments. (**C**) MTT tetrazolium reduction assay (MTT) was used to evaluate proliferation of primary kidney cells derived from *Cdh16^Cre^::Tfeb^fs^* mice. Values are shown as an average (± SEM) of each point in triplicate and normalized versus wild-type mice. Data are representative of three independent experiments. (**D**) MTT proliferation assays of primary kidney cells treated independently with two WNT signaling inhibitors, PKF118-310 and CGP049090, added at different dosages for 24 hr. 0 µm represents the basal proliferation of cells. Values are shown as means (± SEM) of three replicates per point normalized to the vehicle (DMSO), added at the same concentration, and versus the *Cdh16^Cre^ *cells without drug treatment. Results are representative of three independent experiments. Two-way Anova was applied (factors: cell genotype, treatment). (**E**) Immunoblot analysis on primary kidney cells treated with Drug (PKF118-310) or Vehicle (DMSO) for 24 hr at 1.6 µM. Graphs show the densitometry quantifications of Western blot bands. Values are normalized to actin and are shown as averages (± SEM) (Cor, cortex; Med, medulla). (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.016](10.7554/eLife.17047.016)

Treatment with WNT inhibitors ameliorate the disease phenotype {#s2-5}
--------------------------------------------------------------

Primary kidney cells derived from the renal cortex and medulla of *Cdh16^Cre^::Tfeb^fs^ *mice showed significantly higher levels of proliferation compared to wild-type cells ([Figure 5C](#fig5){ref-type="fig"}). We tested whether this hyperproliferative phenotype was sensitive to WNT inhibition. Strikingly, cell proliferation was significantly dampened, in a dose-dependent way, by two small-molecules, PKF118-310 and CGP049090 that specifically inhibit the WNT pathway by disrupting the interaction between β-catenin and TCF4 ([@bib8]) and are known to suppress cell proliferation in several types of cancers, both in vitro and in vivo ([@bib68]; [@bib67]) ([Figure 5D](#fig5){ref-type="fig"}). Moreover, β-catenin and CCND1 protein levels were highly reduced after PKF118-310 treatment ([Figure 5E](#fig5){ref-type="fig"}).

Based on the results obtained in primary kidney cells, we tested whether WNT inhibition could ameliorate the disease phenotype in vivo. P21 *Cdh16^Cre^::Tfeb^fs ^*transgenic animals were treated with daily IP injections of PKF118-310 for 30 days. At the end of the treatment, they showed an almost complete rescue of both cystic and cancer phenotypes ([Figure 6A](#fig6){ref-type="fig"}). Indeed, treated animals showed nearly normal KW/BW ratios ([Figure 6B](#fig6){ref-type="fig"}) and a significant reduction of many parameters of cystic and neoplastic pathology, such as the number and size of cysts and neoplastic papillae, and levels of Ki67 ([Figure 6C and D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, [Figure 6---source data 1](#SD3-data){ref-type="supplementary-material"}). We confirmed that drug-treatment in *Cdh16^Cre^::Tfeb^fs ^*mice suppressed the WNT pathway both at the mRNA and protein levels, as shown by the reduction of the mRNA levels of the WNT direct gene targets Cyclin D1, Myc and Axin2 ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}), by the reduction of Cyclin D1 and MYC proteins ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}) and by the decrease of Cyclin D1-positive nuclei in *Cdh16^Cre^::Tfeb^fs ^*drug-treated mice ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}). Furthermore, WNT inhibition resulted in normalization of expression levels of the gene encoding the transmembrane Glycoprotein nmb (*Gpnmb*) ([Figure 6E and F](#fig6){ref-type="fig"}), a known marker of melanomas, gliomas and breast cancers, which is also overexpressed in *TFE*-fusion *ccRCCs* ([@bib40]; [@bib72]). Interestingly, this gene is a direct target of TFEB, based on promoter ([Table 3](#tbl3){ref-type="table"}) and ChiP-Seq analysis ([@bib57]) ([Table 4](#tbl4){ref-type="table"}).10.7554/eLife.17047.017Figure 6.Treatment with WNT inhibitor attenuates cystic and neoplastic phenotypes.Morphological, histological and biochemical analyses performed on *Cdh16^Cre^::Tfeb^fs^* mice treated with Vehicle (DMSO) or Drug (PKF118-310). (**A**,**B**) Kidney images (**A**) and sizes (KW/BW) (**B**) from *Cdh16^Cre^::Tfeb^fs^* mice injected intraperitoneally (IP) either with vehicle or drug at 0.85 mg/kg. KW/BW ratios are shown as means (± SEM) and values are normalized to the *Cdh16^Cre^ *animals treated with vehicle. Two-way ANOVA was applied (factors: treatment, genotype). (**C**) Ki67 staining of kidneys from *Cdh16^Cre^::Tfeb^fs^* mice after treatment with vehicle or drug. Insets are enlargements of a single cyst. (**D**) Quantification of several parameters related to cysts and papillae performed on kidney sections from vehicle- and PKF118-310-treated *Cdh16^Cre^::Tfeb^fs^* mice. (**E**) Gpnmb mRNA fold activation in kidneys from *Cdh16^Cre^::Tfeb^fs^* and tam-treated *Cdh16^CreErt2^::Tfeb^fs^* mice at different stages. Values are shown as means (± SEM) of at least three mice and each group is normalized to the proper control (respectively *Cdh16^Cre^* and tam-treated *Cdh16^CreErt2^*). (**F**) Gpnmb fold activation in kidneys from *Cdh16^Cre^::Tfeb^fs^* mice treated with vehicle or PKF118-310. Values are shown as means (± SEM) of at least three animals per group and are all normalized versus the *Cdh16^Cre^* mice treated with vehicle. (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-sided Student's *t* test).**DOI:** [http://dx.doi.org/10.7554/eLife.17047.017](10.7554/eLife.17047.017)10.7554/eLife.17047.018Figure 6---source data 1.Numerical data of each parameter showed in [Figure 6D](#fig6){ref-type="fig"} and divided per genotype and treatment.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.018](10.7554/eLife.17047.018)10.7554/eLife.17047.019Figure 6---figure supplement 1.In vivo treatment of *Cdh16^Cre^::Tfeb^fs^* mice with the WNT inhibitor PKF118-310 partially rescues cystic and neoplastic phenotypes.Measurements of different parameters related to the cystic and papillary phenotype on six animals treated with vehicle (DMSO) and six animals treated with drug (PKF118-310). Values are shown as means (± SEM) when appropriate and are represented separately for each animal.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.019](10.7554/eLife.17047.019)10.7554/eLife.17047.020Figure 6---figure supplement 2.In vivo treatment of *Cdh16^Cre^::Tfeb^fs^* mice with the PKF118-310 drug inhibits WNT pathway overactivation.(**A**) *Tfeb, Cyclin* D1, *Myc* and *Axin2* mRNA levels in kidneys from *Cdh16^Cre^* and *Cdh16^Cre^::Tfeb^fs^* mice treated with vehicle or PKF118-310. Values are shown as the average (± SEM) of four animals per group, and are all normalized to the *Cdh16^Cre^* mice treated with vehicle. (**B**) Biochemical analysis performed on *Cdh16^Cre^* and *Cdh16^Cre^::Tfeb^fs^* mice treated with vehicle or PKF118-310. Each replicate is a distinct biological sample. Cyclin D1 and MYC protein levels were quantified by densitometry analysis of Western blot bands. Values are normalized to actin when not specified, and are shown as an average (± SEM) of at least three animals per time-point and genotype. Two-way ANOVA was applied (factors: cell genotype, treatment) (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). (**C**) Cyclin D1 staining performed on drug- and vehicle- treated *Cdh16^Cre^::Tfeb^fs^* mice before and after the hematoxylin counterstaining.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.020](10.7554/eLife.17047.020)10.7554/eLife.17047.021Figure 6---figure supplement 3.Inhibition of autophagy in *Tfeb* overexpressing mice (*Atg7^flox/flox^::Cdh16^Cre^::Tfeb^fs^*) does not affect the cystic phenotype.(**A**) Real-time PCR validation of well-known TFEB direct gene targets whose function is related to the lysosomal and autophagic pathways performed on P30 *Cdh16^Cre^::Tfeb^fs^* mice. Values are shown as the average (± SEM) of at least three *Cdh16^Cre^::Tfeb^fs^* mice and are normalized to wild-type mice (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-sided Student's *t* test). (**B**) P14 and P30 kidney lysates from *Cdh16^Cre^::Tfeb^fs^* animals were evaluated by LC3I/II immunoblot. LC3 active / LC3 total ratios were quantified via densitometry of the Western blot bands (graph). Each replicate is a different biological sample. Values are shown as the average (± SEM) of at least three *Cdh16^Cre^::Tfeb^fs^* mice and are normalized to wild-type lines. (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-sided, Student's *t* test). (**C**) Renal images of (*Atg7^flox/flox^::Cdh16^Cre^::Tfeb^fs^)* double transgenic mice and controls at P30. (**D**) Kidney-to-body weight ratio (KW/BW) from the different genotypes obtained. Values are normalized to the *Atg7^flox/flox^::Cdh16^Cre^ *line and are shown as the average (± SEM) of at least three mice per genotype. One-way Anova was applied (factors: genotype) (\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001). (**E**) PAS and ATG7 staining of kidneys from the different mouse lines.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.021](10.7554/eLife.17047.021)10.7554/eLife.17047.022Table 3.GPNMB expression profiles and CLEAR sites. (**A**) Differentially expression of Gpnmb transcript in KSP_P0 (GSE62977), in KSP_P14 microarray dataset (GSE63376) and in RCC dataset. (**B**) Sequence analysis of the CLEAR sites (i.e. the consensus TFEB binding sites) in the human and murine promoter region of Gpnmb.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.022](10.7554/eLife.17047.022)A**Probe set IDGene symbolGene titleRepresentative public IDEnsemblratio (KSP_P0/CTL)ratio (KSP_P14/CTL)ratio (RCC/CTL)**1448303_atGpnmbglycoprotein (transmembrane) nmbNM_053110ENSMUSG00000029816**10,613589794,926015853141,4101213BGeneScoreSequenceChromABS startABS endTSS_position**Gpnmb0,8731563GGGGCAAGTGACTCchr649036518490365311Gpnmb0,803943ACATCACATGATCTchr6490365874903660070GPNMB0,8484716CCATCACATGATCCchr723286328232863411310.7554/eLife.17047.023Table 4.List of 11 genes shared between the KSP_P0 dataset and from an HeLa TFEB-overexpressing ChIP-Seq dataset.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.023](10.7554/eLife.17047.023)Gene symbolsigned_ratio (KSP_P0/CTL)chromosomestartstoppeak tagsdistance from 5\' end of geneRefSeq IDsymbolIDABS distance**Elf3**1,881188134chr12E+082019789778-712NM_001114309ELF3ETS-related transcription factor Elf-3712**Gna13**1,504591673chr176E+07630533798-58NM_006572GNA13guanine nucleotide-binding protein subunit58**Ankrd12**1,599217835chr189E+069137025150NM_015208ANKRD12ankyrin repeat domain 12 isoform 10**Atp6v1c1**1,658752808chr81E+08104033525150NM_001695ATP6V1C1V-type proton ATPase subunit C 10**Bhlhe40**2,03490115chr35E+065021164100NM_003670BHLHE40class E basic helix-loop-helix protein 400**Gpnmb**10,61358979chr72E+072328652490NM_002510GPNMBtransmembrane glycoprotein NMB isoform b0**Kdm6a**1,58385317chrX4E+0744732628330NM_021140KDM6Alysine-specific demethylase 6A0**Lats2**1,761917857chr132E+0721636098220NM_014572LATS2serine/threonine-protein kinase LATS20**Ppargc1a**2,713649997chr42E+0723891989110NM_013261PPARGC1Aperoxisome proliferator-activated receptor gamma0**Rnf146**1,700903945chr61E+08127588198140NM_030963RNF146ring finger protein 1460**Usp2**2,284889961chr111E+0811925276080NM_004205USP2ubiquitin specific peptidase 2 isoform a0

Autophagy is not required for disease progression {#s2-6}
-------------------------------------------------

Considering the known role of TFEB as a master regulator of the lysosomal-autophagy pathway ([@bib3], [@bib6]; [@bib12]; [@bib15]), and the recent evidence indicating that activation of autophagy driven by MiT/TFE genes plays an important role in pancreatic cancer ([@bib47]), we tested whether autophagy plays a role in *TFE*-tRCC development. We analyzed the expression levels of a well-characterized panel of TFEB target genes known to be involved in lysosomal biogenesis and autophagy in *Cdh16^Cre^::Tfeb^fs^ *mice. Surprisingly, no significant changes in the expression levels of these genes were detected in *Cdh16^Cre^::Tfeb^fs^ *compared to wild type mice, with a few exceptions ([Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}). Consistently, immunoblot analysis of the autophagy marker LC3 in kidneys from transgenic mice did not reveal any significant changes compared to control littermates ([Figure 6---figure supplement 3B](#fig6s3){ref-type="fig"}). Furthermore, to test the role of autophagy in the pathogenesis of *TFE*-tRCC we crossed *Cdh16^Cre^::Tfeb^fs^ *mice with autophagy-deficient *Atg7^flox/flox^ *mice. No changes in kidney size or in the cystic phenotype were observed in TFEB overexpressing/autophagy-deficient double transgenic mice (*Atg7^flox/flox^::Cdh16^Cre^::Tfeb^fs^*), herein referred to *Atg7^flox/flox^::Cdh16^Cre^::Tfeb^fs^*, compared to *Cdh16^Cre^::Tfeb^fs^ *mice ([Figure 6---figure supplement 3C--E](#fig6s3){ref-type="fig"}). Interestingly, most of the double transgenic animals died at approximately 1 month of age, suggesting that the combination of TFEB overexpression with autophagy inhibition in the kidney is toxic. This may be due to the previously described increase in sensitivity to oxidative stress of kidney-specific autophagy-deficient mice ([@bib38]). These results suggest that autophagy does not play a critical role in the development of *TFE*-tRCC phenotype.

Discussion {#s3}
==========

Kidney cancers associated with translocations of *TFE* genes represent a major unmet medical need ([@bib6]; [@bib27]; [@bib40]). Unfortunately, little is known about the mechanisms underlying this type of tumors.

In most cases, *TFEB*-tRCCs are associated to a well-characterized chromosomal translocation involving the TFEB gene and the non-coding Alpha gene, generating the alpha-*TFEB* fusion (t(6;11) (p21.2;q13) ([@bib15]; [@bib30]). Until recent reports, *TFEB* breakpoints were in all cases observed within a 289 bp cluster region (BCR) upstream exon 3, thus retaining the entire TFEB coding sequence ([@bib15]; [@bib6]; [@bib22]). As a consequence, the chromosomal translocation leads to a promoter substitution of the *TFEB* gene, and to a strong up-regulation of *TFEB* transcript and protein up to 60-times ([@bib30]). Only recently, a new breakpoint was identified within exon 4, but the protein size appears to be the same as the wild-type protein ([@bib22]). In rare cases of RCCs, *TFEB* translocation partners were the *KHDBRS2* (*inv*(*6*) (*p21;q11*)) ([@bib40]) and the *CLTC* (*t*(*6;17*) (*p21;q23*)) genes ([@bib17]). The situation of *TFE3* chromosomal translocations appears to be more complicated. *TFE3* was found to be involved in translocations with five known gene partners (i.e. *PRCC, ASPSCR1, SFQP, NONO, CLTC*) leading to the generation of fusion proteins. The identification of multiple *TFE3*-gene partners and the characterization of two *TFE3*-fusion proteins (*TFE3-NONO, TFE3-SFQP*) ([@bib13]) strongly suggested that RCC is caused by *TFE3*, rather than by its partners ([@bib23]). Indeed, *TFE3* fusion protein resulted to be much more stable and transcriptionally active than the wild-type protein ([@bib69]). Together, these data suggest that the first step, and driving force, of the disease pathological cascade is the overexpression of active TFEB and TFE3 proteins, which is likely associated to an increase of their function as transcription factors.

Currently, there are no model systems to study the mechanisms underlying *TFE*-tRCC kidney tumors and to identify and test new therapeutic strategies. Until now, very limited data were available on the biological pathways involved in these tumors. Argani et al. ([@bib4]) reported activation of the mTOR pathway in *TFE*-tRCC patients compared to ccRCCs, as shown by increased phosphorylation levels of the downstream mTOR target S6. Unfortunately, selective mTORC1 inhibition performed on patients with *TFE*-tRCCs did not improve the disease phenotype ([@bib39]). Up-regulation of the MET-tyrosine kinase receptor, which in turn activates HGF-signaling, was detected in *TFE*-tRCC patients by in vitro assays ([@bib63]), but subsequent analyses on TFE3-renal samples failed to identify activated MET protein ([@bib23]). The lack of mechanistic insights in *TFE-*t*RCCs* have hampered the identification of effective therapeutic strategies ([@bib23]). Some patients with metastatic *TFE3-*tRCC have been treated with inhibitors of ErbB receptors and of the mTOR pathway. Unfortunately, most of these patients relapsed after an initial period of remission ([@bib46]; [@bib70]).

The lack of knowledge of the mechanisms underlying *TFE-*t*RCCs* prompted us to generate transgenic mouse models that overexpress *TFEB* in the kidney, thus mimicking the human disease situation. We generated two transgenic mouse models overexpressing *TFEB* in the epithelial cells of the kidney in either a constitutive (*Cdh16^Cre^::Tfeb^fs^*) or an inducible (*Cdh16^CreErt2^::Tfeb^fs^*) manner. A severe renal cystic pathology associated with a significant increase in renal size was observed in these mice. In the constitutive model, cysts arose from the collecting ducts and distal tubules, whereas in the inducible one they derived from proximal and distal tubules.

We observed that cysts were either single- or multi-layered. Epithelial cells lining the mono-layered cysts often lost their cuboidal shape, becoming flattened. Further analyses revealed the presence of protein casts inside the cysts and multi-layered basal membranes in the regions surrounding the cysts, due to collagen deposition. Interestingly, the presence of fibrosis, mBMs and tubular or cystic structures covered by a single layer of flattened, cuboidal, and columnar cells is also observed in human patients affected by *TFEB*-tRCCs ([@bib51], [@bib52]). Finally, in both types of transgenic lines, we observed the presence of highly enlarged cells with a clear cytoplasm, that closely resemble the \'Clear Cells\' found in human patients with RCC ([@bib51]).

Transgenic mice also displayed a higher glucose metabolism, as shown by PET-scan performed in P30 animals suggesting the presence of renal cancer. At P12, *Cdh16^Cre^::Tfeb^fs^ *mice already presented cystic changes together with neoplastic nodules that were Ki67-positive. The progressive hyper-proliferation of these nodules resulted in the development of micropapillae starting from P30, which evolved into neoplastic papillae in 5-month-old mice. Finally, liver metastases positive for PAX8 and CDH16 and neoplastic nests were observed in older animals. These data indicate that these newly generated transgenic lines bear all major histological and phenotypic features of human *TFE*-tRCC ([@bib23]; [@bib51], [@bib52]), thus representing excellent models to study this disease.

To identify the effect of TFEB overexpression on the kidney transcriptome, we performed microarray analysis on kidney samples from P0 *Cdh16^Cre^::Tfeb^fs^* mice. Unexpectedly, transgenic mice did not show a significant induction of the autophagy machinery and crossing of these animals with an autophagy deficient *Atg7^flox/flox^ *mouse line failed to revert the disease phenotype, thus suggesting that autophagy does not play an essential role in the pathogenesis of this disease.

Transcriptome analysis revealed a significant induction of genes involved in the WNT pathway, such as WNT direct target genes *Ccnd1, Myc* and *Axin2* and WNT-related genes *Fzd3, Rnf146* and *Kdm6a*. This transcriptional induction was consistent with increased protein levels of total β-catenin, active β-catenin, CCND1 and pLRP6 (Ser1490)/ LRP6 ratio. Furthermore, an induction of the phospho-GSK3β (Ser9)/ GSK3β ratio, an inactive form of the GSK3β kinase, was detected at later stages. Hyper-activation of the WNT pathway was also observed in cortical and medullary primary kidney cells derived from *Cdh16^Cre^::Tfeb^fs^* mice. Most importantly, luciferase assays performed on HEK-293 and HK-2 cells revealed that TFEB overexpression resulted in a significant enhancement of WNT pathway activation.

WNT signalling is of central importance for the development of many organs and has been implicated in tumor pathogenesis at different sites such as skin ([@bib53]), brain ([@bib74]), liver ([@bib16]) and prostate ([@bib65]). Its activation requires the formation of the WNT signalosome, resulting from the binding of WNT ligands to Frizzled (Fzd) receptors. This mediates the interaction of Fzd with LRP5/6 proteins. Fzd-LRP5/6 hetero-oligomerization is required to sequester the β-catenin degradation complex, containing several kinases such as GSK3 and CK1. GSK3 is then able to phosphorylate LRP but not β-catenin. Active β-catenin translocates into the nucleus and activates its target genes, such as *MYC*, *AXIN2* and *CCND1* ([@bib14]), by interacting with the TCF4/LEF1 transcription factors ([@bib66]).

Interestingly, hyper-activation of the WNT pathway was recently detected in a melanoma cell line in which MITF, another member of the MiT/TFE family, was overexpressed, leading to an expansion of the endo-lysosomal compartment that in turn was able to concentrate and relocate the WNT signalosome/destruction complex and consequently to enhance WNT signaling ([@bib50]). In addition, several studies have linked alterations in the regulation of the β-catenin pathway to abnormalities of kidney development and function ([@bib64]). Indeed, β-catenin is necessary for proper regulation of the *PKD1* promoter ([@bib55]), that is mutated in 85% of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Furthermore, the WNT pathway is also known to play a role in renal tumor formation, such as in VHL syndrome ([@bib48]) and Wilm's tumor ([@bib26]; [@bib73]; [@bib24]). Mice lacking the *Apc* gene specifically in the kidney are prone to the development of cystic renal cell carcinomas ([@bib56]). Finally, cytoplasmic accumulation of β-catenin was observed in patients with *TFE3*-tRCC, suggesting the presence of a possible link between *TFE*-factors and WNT-signaling components ([@bib11]). Together these studies reveal a strong link between hyper-activation of WNT signaling and tumorigenesis in the kidney and reinforce our finding of WNT hyper-activation in TFEB transgenic mice as a critical step of the disease pathogenesis.

Based on this evidence, we postulated that treatment with WNT inhibitors had beneficial effects on *TFE*-tRCCs. To test this hypothesis, we treated primary kidney cells from *Cdh16^Cre^::Tfeb^fs^* mice with two small molecules, PKF118-310 and CGP049090, able to inhibit the WNT pathway by disrupting the interaction between β-catenin and TCF-4 ([@bib8]). Drug treatments significantly reduced the hyper-proliferation rate observed in cells from transgenic mice, bringing it to normal levels. Therefore, we sought to reproduce these data in vivo by treating *Cdh16^Cre^::Tfeb^fs^* mice with WNT inhibitors. Administration of the PKF118-310 molecule or vehicle for 30 days resulted in a substantial reduction of several important parameters, such as kidney size, cyst number and size, Ki67 index and the number of neoplastic papillae. Moreover, drug-treated *Cdh16^Cre^::Tfeb^fs^* animals showed a significant decrease in the mRNA levels of Gpnmb, a known marker of melanomas, gliomas and breast cancer, which was reported to be overexpressed in *TFE*-fusion *ccRCCs* ([@bib40]; [@bib71]). Interestingly, we also found that Gpnmb is a direct transcriptional target of TFEB ([@bib57]).

This study provides direct evidence that overexpression of *TFEB* in the kidney is able to generate a severe cystic pathology associated with the development of kidney cancer and liver metastases, thus mimicking the cancer phenotype associated with human *TFE*-fusion *ccRCCs* chromosomal translocations. Thus, the transgenic mouse lines that we generated represent the first genetic animal models of renal cell carcinoma. The study of these mice revealed that WNT activation plays a crucial role in *TFE-*t*RCCs* and that WNT inhibitors can be used to rescue the phenotype of our transgenic mouse models, suggesting that targeting WNT signaling could be a promising therapeutic approach for the treatment of *TFE-*t*RCC* patients.

Materials and methods {#s4}
=====================

Mouse models {#s4-1}
------------

*Tfeb^fs/fs^* transgenic mice (generated by Dr. Settembre \[[@bib58]\]) were crossed with a kidney-specific *Cdh16^Cre^ (Cdh16*, Cadherin 16) (Jackson laboratories RRID:[IMSR_JAX:012237](https://scicrunch.org/resolver/IMSR_JAX:012237)) and *Cdh16^CreErt2 ^*(generated by Dr. Peters \[[@bib31]\]) mice. The *Atg7* conditional KO mice ([@bib28]) (*Atg^flox/flox^* mice) was a generous gift from T.Eissa. Mice were crossed with *Cdh16^Cre^*and *Tfeb^fs/fs^ *mice to obtain kidney-specific Atg7 deletion and TFEB overexpression (*Atg^flox/flox^: :Cdh16^Cre^::Tfeb^fs^*). All mice used were maintained in a C57BL/6 background genotype. *Cdh16^Cre^*and *Cdh16^Cre^::Tfeb^fs^* mice were injected intra-peritoneally (IP) with tamoxifen at a dosage of 100 μg/g of mouse weight for three consecutive days to obtain an efficient recombination. For the Kidney to Body weight ratio experiments, we analyzed at least three animals per genotype/sex/condition, but often the number was higher than 5. Experiments were conducted in accordance with the guidelines of the Animal Care and Use Committee of Cardarelli Hospital in Naples and authorized by the Italian Ministry of Health.

Cell culture, transfections and plasmids {#s4-2}
----------------------------------------

Primary kidney cells were obtained following the protocol described in Leemans *et al. *([@bib33]). Briefly, kidneys were collected and uncapsulated. Tissue from the outer cortex and inner medulla was cut into approximately 1 mm^3^ pieces, and subsequently digested by 1 mg/ml collagenase type 1A (Sigma- Aldrich, Saint Louis, MO) at 37°C for 1 hr. After washing cells with PBS, primary TECs were grown to confluence in DMEM-F12 culture medium supplemented with 10% FCS, 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine (Gibco; Invitrogen Corp.), 1% ITSe and 1% S1 hormone mixture (Sigma-Aldrich) and were cultured in 5% CO~2~ at 37 degrees. TECs were identified by characteristic cobblestone-shaped morphology. Tfeb overexpression was confirmed by FLAG immunoblot ([Figure 2](#fig2){ref-type="fig"}). HEK293 (CRL-1573, RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)) and HK2 (CRL-2190, RRID:[CVCL_0302](https://scicrunch.org/resolver/CVCL_0302)) cells were purchased from ATCC. The identity of these cells have been confirmed by STR profiling (<http://web.expasy.org/cellosaurus/CVCL_00459>) (<http://web.expasy.org/cellosaurus/CVCL_0302>). No mycoplasma contamination was detected in these cells. HEK293 cells were cultured in DMEM (Euroclone) supplemented with 10% FBS, 100IU/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine (Gibco; Invitrogen Corp.). HK2 cells were grown in DMEM-F12 (Invitrogen) supplemented with 5% FBS, 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine (Gibco; Invitrogen Corp.) and 1% ITSe. Cells were grown at 5% CO~2~ at 37 degrees. Human full-length TFEB-FLAG was previously described ([@bib58]). The TopFlash and FopFlash plasmids (Upstate), the pCS2+MT-Myc-tagged β-CATENIN (full-length β-CATENIN), and the Evr2-Tcf1E plasmid (Tcf1E) were kindly provided by Dr. M. Plateroti.

Cells were transfected with Lipofectamine LTX and Plus reagent (Invitrogen) following the manufacturer's protocol. Luciferase activity was measured 48 hr post-transfection using the Dual-Luciferase Reporter Assay System (Promega). To normalize transfection efficiency in reporter assays, the HEK293 and HK2 cells were co-transfected with a plasmid carrying the internal control reporter *Renilla reniformis* luciferase driven by a TK promoter (pRL-TK; Promega). Data are representative of three independent experiments and statistical significance was determined using Student\'s *t*-test. p\<0.05 was considered as significant.

In vitro drug treatments and MTT proliferation assay {#s4-3}
----------------------------------------------------

Cultured primary kidney cells derived from the cortex and medulla of *Cdh16^Cre^*and *Cdh16^Cre^::Tfeb^fs^* mice were seeded in 96-well plates at the density of 5 × 10^3 ^cells/well, maintained overnight at 37°C, and incubated in the presence of the test compounds at the different concentrations. PKF118-310 and CGP049090 were added at different dosages (0 µm, 0.2 µm, 0.4 µm, 0.8 µm, 1.6 µm, 3.2 µm) for 24 hr. 0 µm represents the basal proliferation of cells after 48 hr of plating. MTT assay was used to assess cell proliferation. Briefly, 5 mg of MTT powder was solubilized in 1 mL of PBS and filtered. Ten microliter of this solution was added to 100 μl of cell culture medium without phenol red. At the end of the incubation time, cells were washed twice with PBS and incubated with MTT-media solution to form formazan crystals. After 4 hr, media was removed and 100 μl/well of a solubilisation solution was added to the cells (2.1 mL HCl 10 N, 500 mL isopropanol) for 4 hr at 37°C to obtain a complete solubilization of the crystals. As a readout, absorbance of the 96-well plate was measured recording the Optical Density (OD) at 570 nm with a microplate spectrophotometer system. Results are representative of three independent experiments performed on three different *Cdh16^Cre^* and *Cdh16^Cre^::Tfeb^fs^* mice. *T*-test is referred to cells without drug (0 µm) taken from *Cdh16^Cre^::Tfeb^fs^* mice versus cells without drug (0 µm) taken from *Cdh16^Cre^*mice. Data are representative of three independent experiments, and statistical significance was determined using Student\'s *t*-test. p\<0.05 was considered as significant.

In vivo drug treatments {#s4-4}
-----------------------

P21 *Cdh16^Cre^*and *Cdh16^Cre^::Tfeb^fs^* mice were injected IP daily, from Monday to Friday, with the PKF118-310 drug at the dose of 0.85 mg/kg or with an equal amount of vehicle (DMSO). After 30 days from the beginning of the treatment, animals were sacrificed and kidneys were collected and weighted and processed for further analyses. Six animals for each group and genotype were collected.

Biochemical analysis {#s4-5}
--------------------

Plasma urea was measured using standardized clinical diagnostic protocols of the Academical Medical Center Amsterdam. Albumin (Bethyl Laboratories, Montgomery, TX) was measured in urines collected for 24 hr in metabolic cages and was analyzed by following the manufacturer's instructions.

High-frequency ultrasound and PET/CT scan analyses {#s4-6}
--------------------------------------------------

All the imaging procedures were performed with mice under general anesthesia. Anesthesia was produced in an induction chamber, saturated with 5% isoflurane (Iso-Vet 1000 mg/g Inhalation Vapor, Piramal Healthcare UK Ltd., Northumberland, UK) in oxygen (2 L/min) and subsequently maintained during all procedures with a conenose delivering isoflurane at 1.5% in oxygen at 2 L/min.

For High-frequency ultrasound, each mouse was placed in dorsal recumbency on a dedicated, heated, small animal table (VEVO Imaging Station 2, FUJIFILM VisualSonics, Inc., Toronto, Ontario, Canada) and hairs were removed with a small clipper and then with the application of a depilatory cream, and a pre-warmed ultrasound-coupling gel was applied to the skin to improve ultrasound transmission and reduce contact artefacts. A 40 MHz transducer (MS 550 D, FUJIFILM VisualSonics, Inc., Toronto, Ontario, Canada) was mounted on the dedicated stand of the imaging station, and B-mode and Color-Doppler mode images were obtained on the ultrasound equipment (VEVO 2100, FUJIFILM VisualSonics, Inc., Toronto, Ontario, Canada).

Positron emission tomography (PET) coupled with computed tomography (CT) was performed with a dedicated small animals PET/CT scanner (eXplore Vista, GE Healthcare), with a trans-axial field of view of 6.7 cm and an axial field of view of 4.8 cm. Animals, fasted overnight, were injected under general anesthesia in the lateral caudal vein with 300 µCi of \[^18^F\]-fluorodeoxyglucose (FDG). Mice were left to recover from anesthesia under a heating lamp and PET/CT acquisitions were started after 90 min of biodistribution. Static emission scans of 30 min with energy window of 250--700 keV were acquired. The PET datasets were reconstructed by 2D FORE/3D OSEM algorithm and corrected for random coincidences, scatter, physical decay to the time of injection (voxel size: 0.3875 × 0.3875 × 0.775 mm^3^). The mean specific uptake value (SUV) was obtained for each region of interest using the visualization and analysis software of the scanner (version 4.11 Build 701, MMWKS Image Software: Laboratorio de Imagen, HGUGM, Madrid, Spain).

Survival analysis {#s4-7}
-----------------

Survival curves were calculated for a period of 8 months on a total of 15 *Cdh16^Cre^::Tfeb^fs^* mice, 10 *Cdh16^CreErt2^::Tfeb^fs^* mice (tam P12), 12 *Cdh16^CreErt2^*mice (tam P14) and 12 *Cdh16^CreErt2^::Tfeb^fs^* mice (tam P30) grown in the same animal facility, all in same background (C57BL/6). Values were plotted by the product-limit method of Kaplan and Meier; statistical analyses were carried out applying the Log Rank (Mantel-Cox) test.

Quantitative real-time PCR {#s4-8}
--------------------------

Total RNA was isolated from frozen samples lysed in Trizol (Life Technologies) using a TissueLyser (Qiagen) and following the recommended manufacturer's protocol. Reverse transcription was performed using QuantiTect Rev Transcription Kit (Qiagen). Finally, real-time PCR was performed using SYBR Green (Roche Diagnostics) and performing the reaction in the LightCycler System 2.0 (Roche Applied Science). The parameters of real-time PCR amplification were defined according to Roche recommendations. To quantify gene expression, Gapdh mRNA expression was used as an internal reference. All the values are shown as fold activation respect to w-type levels. Data are representative of three independent experiments and statistical significance was determined using Student\'s *t*-test. p\<0.05 was considered as significant.

The following primers were used in this study: Gapdh; forward (fw) tgcaccaccaactgcttagc, reverse (rev) tcttctgggtggcagtgatg; Tfeb; fw gcagaagaaagacaatcacaa, rev gccttggggatcagcatt; Ccnd1; fw ccttgactgccgagaagttgtg, rev gttccacttgagcttgttcacca; Axin2; fw gatgcatcgcagtgtgaagg, rev ggttccacaggcgtcatctc; Myc; fw ccagcagcgactctgaagaa, rev acctcttggcaggggtttg; Fzd3; fw gcatctgggagacaacatgg, rev caggtctggacgactcatctg; Rnf146; fw agcggaggagaaaagactgc, rev acatagccctttctcggtccg; Kdm6a; fw tgacagcggaggagagggag, rev ccttcatcctggcgccatct; Cdkn1a; fw gtctgagcggcctgaagatt, rev caatctgcgcttggagtgat; HbEgf; fw tccacaaaccagctgctacc, rev ccttgtggcttggaggagaa; Pak1; fw ttcctgaaccgctgtcttga, rev tcaggctagagaggggcttg; Areg; fw tattggcatcggcatcgtta, rev tgcacagtcccgttttcttg; Crk; fw cgcgtctcccactacatcat, rev tctcctattcggagcctgga; Tgfa; fw agtgcccagattcccacact, rev cgtacccagagtggcagaca; Gpnmb, fw tggctacttcagagccacca, rev ggcatggggacatctgctat.

Microarray hybridization {#s4-9}
------------------------

Total RNA (3 μg) was reverse transcribed to single-stranded cDNA with a special oligo (dT) 24 primer containing a T7 RNA promoter site, added 3\' to the poly-T tract, prior to second strand synthesis (One Cycle cDNA Synthesis Kit by Affymetrix, Fremont, CA). Biotinylated cRNAs were then generated, using the GeneChip IVT Labeling Kit (Affymetrix). Twenty microgram of biotinylated cRNA was fragmented and 10 μg hybridized to the Affymetrix GeneChip Mouse 430A_2 microarrays for 16 hr at 45°C using an Affymetrix GeneChip Fluidics Station 450 according to the manufacturer\'s standard protocols.

For the analysis at P0, the total RNA was extracted from the kidney of three *Cdh16^Cre^::Tfeb^fs^* mice and of two control *Cdh16^Cre^* mice. For the analysis at P14, total RNA was extracted from the kidney of three *Cdh16^Cre^::Tfeb^fs^* P14 mice and three control *Cdh16^Cre^ P14* mice.

Microarray data processing {#s4-10}
--------------------------

The data discussed in this publication have been deposited in NCBIs Gene Expression Omnibus (GEO) ([@bib18]) and are accessible through GEO Series accession number GSE62977 (KSP_P0 dataset) and GSE63376 (KSP_P14 dataset) (KSP, Kidney specific). Low-level analysis to convert probe level data to gene level expression was performed using Robust Multiarray Average (RMA) implemented using the RMA function of the Bioconductor project ([@bib19]).

Statistical analysis of differential gene expression {#s4-11}
----------------------------------------------------

For each gene, a Bayesian t-test (Cyber-t) ([@bib9]) was used on RNA normalized data to determine if there was a significant difference in expression between *Cdh16^Cre^::Tfeb^fs^* mice versus *Cdh16^Cre^*mice both at P0 (GSE62977-KSP_P0 dataset) and at P14 (GSE63376- KSP_P14 dataset). p-Value adjustment for multiple comparisons was done with the False Discovery Rate (FDR) of Benjamini-Hochberg ([@bib25]). The threshold for statistical significance chosen was FDR≤0.05. In the KSP_P0 dataset, we selected 361 probe-sets corresponding to 294 significantly induced genes (GSE62977). In the KSP_P14 dataset, we selected 729 probe-set corresponding to 628 genes (GSE63376).

(Immuno-) histological analysis {#s4-12}
-------------------------------

Formalin-fixed, paraffin-embedded kidney sections (4 µm) were analyzed using standard hematoxylin and eosin (HE) staining, periodic acid Schiff (PAS) staining, or Sirius Red (SR) staining. For immunohistochemistry procedures, sections were subjected to heat-mediated antigen retrieval procedure (10 mM citrate buffer pH 6.0) followed by 1 hr preincubation with normal goat serum (1:200; DakoCytomation, Glostrup, Denmark). After blocking of endogenous peroxidase activity for 15 min in 0.1% H~2~O~2~ in water, sections were incubated with primary antibodies diluted in 1% BSA in PBS. Following incubation with secondary antibody, immune reactions were revealed using NovaRed or diaminobenzidine chromogen and counterstained with hematoxylin, dehydrated, and mounted.

Primary antibodies: rabbit polyclonal anti-megalin (1:750, Pathology LUMC, Leiden, the Netherlands), goat polyclonal anti-uromodulin (1:4000, Organon Teknika-Cappel,Turnhout, Belgium), rabbit polyclonal anti-aquaporin-2 (1:4000 Calbiochem, Amsterdam, The Netherlands), rabbit polyclonal anti-β-catenin (1:500, Santa Cruz sc-7199, RRID:[AB_634603](https://scicrunch.org/resolver/AB_634603)), rabbit monoclonal anti-active β-catenin (1:800, Cell Signaling \#8814, RRID:[AB_11127203](https://scicrunch.org/resolver/AB_11127203)), rabbit polyclonal anti-cadherin16 (1:300, Novus NBP159248, RRID:[AB_11046440](https://scicrunch.org/resolver/AB_11046440)), rabbit polyclonal anti-ATG7 (1:300, Santa Cruz sc-33211, RRID:[AB_2062165](https://scicrunch.org/resolver/AB_2062165)), rabbit monoclonal anti-Ki67 (ABCAM ab16667, clone SP6, RRID:[AB_302459](https://scicrunch.org/resolver/AB_302459), 1:200), a rabbit polyclonal anti-PAX8 antibody (Proteintech, 10336-1-AP, RRID:[AB_2236705](https://scicrunch.org/resolver/AB_2236705), 1:1000) and a mouse monoclonal anti-Cytokeratin 7 (Abcam, ab9021, RRID:[AB_306947](https://scicrunch.org/resolver/AB_306947), 1:500). Secondary antibodies: anti-rabbit envision HRP (DakoCytomation, Glostrup, Denmark), rabbit-anti-goat HRP (1:100), power rabbit poly-HRP (Biocare Medical, M4U534L). For staining with Sirius Red, de-paraffinized sections were incubated in 0.2% phosphomolybdic acid hydrate for 5 min and 0.1% Sirius red for 90 min. Subsequently, sections were incubated for 1 min in saturated picric acid and then placed in 70% ethanol, dehydrated and mounted.

Quantitative histology {#s4-13}
----------------------

Histomorphometric analysis were conducted on PAS and Ki67-stained sections. For the cyst characterization, cyst number and area was calculated on PAS sections from three animals per genotype and group. Cysts were hand-annotated and measured in the outer and inner cortex, and the outer and inner medulla. Finally, they were sub-divided according to their size.

For the analyses performed on the drug- and vehicle-treated animals, the analysis was conducted on Ki67-stained sections. The number and size of the cysts were defined within the areas identified by the pathologist using ImageScope (Leica-Biosystems Nussloch GmbH).

Using the same method, the number of papillae was counted and the proportion of Ki-67 positive nuclei on the total number of nuclei within the papillae was calculated. For these analyses, a total of six *Cdh16^Cre^::Tfeb^fs^* vehicle (DMSO)-treated and six *Cdh16^Cre^::Tfeb^fs^* drug (PKF118-310)-treated animals were evaluated.

Antibodies and western blotting {#s4-14}
-------------------------------

Tissues were microdissected and disrupted using a TissueLyser (Qiagen). Cells or tissues were lysed by solubilisation in lysis buffer (50 mM Tris at pH 7.9, 1% Triton X-100, 0,1% Tween 20, 150 mM NaCl, 5 mMMgCl2, 10% glycerol) containing phosphatase (Roche) and protease (Sigma) inhibitors. Protein concentration was measured by the Bradford method. Samples were mixed with Laemmli lysis buffer, boiled and resolved by SDS-PAGE. Thereafter, proteins were blotted onto polyvinylidene fluoride (PVDF) membranes and blocked for 1 hr with non-fat 5% milk or 5% BSA diluted in 1X TBS, 0,1% Tween 20, according to the primary antibody protocol. Membranes were incubated with primary antibodies overnight. Visualization was made by incubation with corresponding HRP-labeled secondary antibodies (Calbiochem) followed by enhanced chemiluminescence (ECL) (Perkin Elmer, Waltham, MA). Membranes were developed using a Chemidoc UVP imaging system (Ultra-Violet Products Ltd) and densitometric quantification was performed in unsaturated images using ImageJ (NIH).

For Western blots, the following antibodies were used: anti-FLAG M2-HRP (Sigma, cat. A8592, RRID:[AB_439702](https://scicrunch.org/resolver/AB_439702), 1:1000), anti-actin (Sigma, cat. A2066, RRID:[AB_476693](https://scicrunch.org/resolver/AB_476693), 1:5000), anti-βtubulin (Sigma, cat. T8328, RRID:[AB_1844090](https://scicrunch.org/resolver/AB_1844090) 1:1000), anti-Human/Mouse/Rat Pan-Akt (R&D, cat. MAB2055, RRID:[AB_2224581](https://scicrunch.org/resolver/AB_2224581), 1:500), Phospho-Akt (Ser473) (D9E) Cell Signaling, cat. \#4060, RRID:[AB_2315049](https://scicrunch.org/resolver/AB_2315049), 1:1000), anti-human, mouse, and rat ERK1/ERK2 (R&D, cat.216703, RRID:[AB_2140121](https://scicrunch.org/resolver/AB_2140121), 1:2000), anti-Human/Mouse/Rat Phospho- ERK1(T202/Y204)/ERK2 (T185/Y187) (R&D, cat. AF1018, RRID:[AB_354539](https://scicrunch.org/resolver/AB_354539) 1:1000), anti-β-catenin (BD, cat. 610154, RRID:[AB_397555](https://scicrunch.org/resolver/AB_397555) 1:500), anti-active β-catenin (Cell Signaling, cat. \#8814, RRID:[AB_11127203](https://scicrunch.org/resolver/AB_11127203) 1:1000), anti-Cyclin D1 (Cell Signaling, cat. \#2978, RRID:[AB_10692801](https://scicrunch.org/resolver/AB_10692801) 1:1000), anti-LRP6 (Cell Signaling, cat. \#3395, RRID:[AB_1950408](https://scicrunch.org/resolver/AB_1950408) 1:1000), anti-phospho-LRP6 (Ser1490) (Cell Signaling, cat. \#2568, RRID:[AB_2139327](https://scicrunch.org/resolver/AB_2139327) 1:1000), anti-GSK3β (Cell Signaling, cat. \#9315, RRID:[AB_490890](https://scicrunch.org/resolver/AB_490890) 1:1000), anti-phospho-GSK3β (Ser9) (Cell Signaling, cat. \#9323, RRID:[AB_2115201](https://scicrunch.org/resolver/AB_2115201) 1:1000), anti MYC (Cell Signaling, cat. \#5605, RRID:[AB_1903938](https://scicrunch.org/resolver/AB_1903938) 1:1000).

Statistical analysis {#s4-15}
--------------------

GraphPad Prism (GraphPad Software, San Diego, CA) was used for all statistical analysis. Statistical analyses of data were performed using Student's t-test. One-way ANOVA and Tukey's post-hoc tests were performed when comparing more than two groups relative to a single factor (time or treatment/genotype). Two-way and three-way ANOVA and Tukey's post-hoc tests were performed when comparing more than two groups relative to two or more factors. Mantel-Cox test was used for the survival analysis. p\<0.05 was considered significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by a Reviewing Editor and Sean Morrison as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors describe a new mouse model of TFEB overexpression in the kidney to mimic renal tumors with translocation-induced gain of function of TFE transcription factors. TFEB overexpression results in cyst formation and neoplastic lesions in the kidney. Gene expression studies revealed dramatic induction of genes in the WNT signaling pathway in the affected kidneys, and inhibitors of this pathway significantly ameliorated disease in mice.

Essential revisions:

1\) The mouse model should be described in more detail, particularly the prevalence and size of tumor nodules, whether the primary tumors display local invasion, and the incidence of metastasis to the liver.

2\) The presence of apparent liver metastases from the renal tumors is significant but requires validation. Can the authors perform molecular or other analyses to confirm that the liver lesions arise from tumors in the kidney?

3\) [Figure 6](#fig6){ref-type="fig"}: Please provide evidence by IHC or PCR that the WNT pathway has been suppressed in the drug-treated kidneys.

4\) It is surprising that, based on expression analysis of a few markers, cysts appear to develop from different cell types in the inducible and non-inducible lines. The authors should provide an explanation for this unusual phenomenon, and ideally use additional markers to strengthen their conclusion.

10.7554/eLife.17047.030

Author response

*1) The mouse model should be described in more detail, particularly the prevalence and size of tumor nodules, whether the primary tumors display local invasion, and the incidence of metastasis to the liver.*

We observed neoplastic nodules, starting from P12, in all *KSPcdh16/Tcfeb* and *indKSPcdh16/Tcfeb* mice (on a total of 43 analysed mice), with a size ranging from 0.102 to 2.93 mm and sometimes presenting local invasion of the surrounding stroma as shown by new [Figure 2I](#fig2){ref-type="fig"}. We identified liver metastases ranging from 0.9 to 3.8 mm, in both *KSPcdh16/Tcfeb* and *indKSPcdh16/Tcfeb* mice. Five mice out of a total of 21 *KSPcdh16/Tcfeb* mice analysed over three months of age (an incidence of 23%) developed liver metastases. This information has been included in the text.

*2) The presence of apparent liver metastases from the renal tumors is significant but requires validation. Can the authors perform molecular or other analyses to confirm that the liver lesions arise from tumors in the kidney?*

As already shown in [Figure 2L](#fig2){ref-type="fig"}, liver metastases were positive for PAX8, that is a well-established marker for primary and metastatic RCC (Ozcan A. *et al.*, Arch Pathol Lab Med. 2012; Shen SS. *et al.*, Arch Pathol Lab Med. 2012) and for *KSP*-CDH16, which is a specific renal protein, that is not expressed in other tissues (Shen SS. *et al.*, Arch Pathol Lab Med. 2012). Indeed *Ksp*-Cdh16 promoter has been used to drive renal CRE-specific expression in this study and in a number of other studies (Shao X., *J Am Soc Nephrol.* 2002; Kai T., *J Pathol.* 2016). Liver metastases were instead negative for the bile ducts and cholangiocarcinoma marker CK7 (Cytokeratin 7), consistent with their renal origin ([Figure 2L](#fig2){ref-type="fig"}). This information has been included in the text. We also show that the *KSP*-CDH16 protein was detectable together with the FLAG on liver metastases by Western blot, while healthy hepathic tissue did not show any *KSP*-CDH16 protein expression (see figure below).10.7554/eLife.17047.024Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.17047.024](10.7554/eLife.17047.024)

3\) [Figure 6](#fig6){ref-type="fig"}: Please provide evidence by IHC or PCR that the WNT pathway has been suppressed in the drug-treated kidneys.

As suggested by the reviewer, to check if the WNT pathway was suppressed in drug-treated animals we quantified mRNA levels of the well-established WNT direct gene targets CyclinD1, c-Myc and Axin2 (Clevers 2006), which were significantly induced in the *KSPcdh16/Tcfeb* mouse model. We first validated their induction in vehicle-treated *KSPcdh16/Tcfeb* mice and subsequently demonstrated their suppression in drug-treated *KSPcdh16/Tcfeb* mice. Moreover, biochemical analysis showed a reduction of CyclinD1 and c-MYC proteins in drug-treated mice. Finally, IHC analysis showed a significant decrease of CyclinD1-positive nuclei in drug-treated mice. These data have been included in [Figure 6---figure supplementary 2](#fig6s2){ref-type="fig"}.

*4) It is surprising that, based on expression analysis of a few markers, cysts appear to develop from different cell types in the inducible and non-inducible lines. The authors should provide an explanation for this unusual phenomenon, and ideally use additional markers to strengthen their conclusion.*

We agree with the reviewer's observation and have now included a discussion of this issue in the text. Previous studies on mouse models of polycystic kidney disease have shown that cysts may originate from different cell types (Latinga Van Leeuwen IS. *et al.*, Hum Mol Genet. 2007; Happé H. *et al.*, Hum Mol Genet. 2009; Leonhard WN. *et al.*, J Am Soc Nephrol. 2016). These differences can be explained by different sensitivities to stimuli of different renal segments at different developmental stages (Latinga Van Leeuwen IS. *et al.*, Hum Mol Genet. 2007; Happé H. *et al.*, Hum Mol Genet. 2009; Leonhard WN. *et al.*, J Am Soc Nephrol. 2016; Piontek K. *et al.*, Nat Med. 2007). As part of a separate ongoing, and still unpublished study, Dr. Peters (co-author of our paper) crossbred iKsp-Pkd1del mice with LacZ reporter mice to visualize the pattern of Cre activity upon Tamoxifen administration. She showed that Tamoxifen at either P10,11,12 or at P18,19,20 results in a similar pattern of Cre activity, whereas the cystic phenotype is quite different. Notably, Pkd1 inactivation at P10 rapidly leads to severe cyst formation specifically in the region with the least Ksp-Cre activity, suggesting that this region of the nephron is especially sensitive to cyst formation during a developmental stage. By contrast, Pkd1 deficient cells from the inner medulla, rarely develop cysts. These experiments confirmed the previous indication that different renal segments have different sensitivities and that these vary over time.
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